Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis
about
Acute pancreatitis as a complication of childhood cancer treatmentSurgical management of complications of multimodal therapy.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginasePolymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.General control nonderepressible 2 deletion predisposes to asparaginase-associated pancreatitis in mice.Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2The adolescent and young adult with cancer: state of the art-- acute leukemias.The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment.Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.Asparaginase-associated pancreatitis in children.Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.A critical review on properties and applications of microbial l-asparaginases.Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.Three-dimensional environment renders cancer cells profoundly less susceptible to a single amino acid starvation.Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia.Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.[Acute myelomonocytic leukemia eosinophilic revealed by acute pancreatitis].The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children With Acute Lymphoblastic Leukemia.Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.Relationship between modified CT severity index and clinical features of L-asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia.Pancreatic pseudocyst in an adult patient after treatment with pegylated asparaginase.Comparison of Native Escherichia Coli L-Asparaginase Versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP), in Extranodal NK/T Cell Lymphoma, Nasal Type (NTCL).Galactose protects against cell damage in mouse models of acute pancreatitis
P2860
Q26766231-2682E990-688B-49F3-86C5-7F33FA8659E0Q33400344-2C3C883E-FE2A-4573-A1B9-0FA29D7F3A90Q33557148-C45B525C-5B58-4626-B7C9-1DE3E2C8E24FQ33680270-664C92BA-3FBF-4ABF-A47B-25BC3BDF2488Q34400424-0AD218AB-6A44-4614-BAC4-8988CA0B3CE1Q34644733-0B550D49-978A-4BDE-9B60-B67146B7C75DQ35758669-3D7FCC6E-3818-4CC2-B7F2-F2A597BC8BB5Q35930217-43AEC34B-4154-4129-B0B0-01277042710DQ36163029-7D1FA84D-8D0E-4B42-95D3-1F506858298CQ36762608-C81B634A-5086-48BD-B2D8-3111856E7D00Q37071811-E8166A24-BEEB-48CA-8D51-32ADDBF46234Q37078283-E307ACCD-E463-4278-A25D-F057F7C48112Q37134753-B725A529-CFC7-4D17-A96E-BF94CB6D75BDQ37341948-0F406116-708E-4C13-A64B-7AC262234516Q37385443-0BEBE5F2-3764-46B1-BD37-DA19BC56E317Q37883008-C7A071B5-0469-4A70-A776-FFC9C81F0CFFQ37914185-9AEBB5BD-8971-44B9-8252-790C983BACA7Q38036389-0F8CBAF4-405A-4078-8126-3B8F3583D830Q38248280-C0229943-C8A2-4AAC-9C36-88AB6026CA12Q38417141-6151C8CA-4B80-4E46-B1BE-955806C47A7BQ38696311-E7312147-4175-4F46-A09E-E4F0B099B9A9Q38748699-C7981B20-305E-4B9D-B9E7-52CCB58CA506Q38779952-C05F854B-4A38-4E79-9AF3-910274A4A11CQ39095939-53E5E51A-D1F9-4FF3-9D74-675220AAD1EDQ39785801-F18C7AD0-D087-4F1F-9996-3CA959EC7ACDQ40609832-23CBBA53-5965-4A41-8E6B-3D31490A0741Q42638853-44684801-3673-421C-B0EA-0203D79C489EQ43174427-451CCE59-F99E-49EE-9385-B7FD2F72764FQ45985775-383BF05D-D3D4-49D3-80BB-16CEC6B0A092Q45994014-E4B1A097-4D4F-44D8-800B-A1D72EABE130Q46540888-39DB9511-2F67-4D0A-8885-D9C49CAEC996Q48029395-957FB017-32FC-47A7-AE6D-30C7784C822AQ51620499-6C9D5381-C175-4CF9-A9F7-AEA294F6ACE6Q53062852-F1239324-287E-4CDE-8F07-A85A17E7E4FCQ53222073-35BEDDD1-E70E-423D-96DF-64A8C695C9D8Q54222267-894A99BD-0D56-4263-8142-B6A8D08E3F88Q57110460-5179E720-9E3B-4D17-B7A0-46DD7864DC03
P2860
Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical course and outcome in ...... ginase-associated pancreatitis
@en
Clinical course and outcome in ...... inase-associated pancreatitis.
@nl
type
label
Clinical course and outcome in ...... ginase-associated pancreatitis
@en
Clinical course and outcome in ...... inase-associated pancreatitis.
@nl
prefLabel
Clinical course and outcome in ...... ginase-associated pancreatitis
@en
Clinical course and outcome in ...... inase-associated pancreatitis.
@nl
P2093
P2860
P356
P1476
Clinical course and outcome in ...... ginase-associated pancreatitis
@en
P2093
Donna E Levy
Lewis B Silverman
Stephan D Voss
Stephen E Sallan
Susan L Kearney
P2860
P304
P356
10.1002/PBC.22076
P577
2009-08-01T00:00:00Z